Cipla Could Provide Open Access To Patent For First-Line ARV
LiveMint: Cipla may put patent for new HIV drug in open access pool
“Cipla Ltd, which competed with multinational drug firms by cutting HIV treatment cost to a fraction of the prevailing rate, is hoping to make a similar impact with a new four-drug combination to treat HIV/AIDS in infants and children. The drug is in the advanced stage of development. The Indian firm led by Y.K. Hamied, which will own the intellectual property rights of the first-line antiretroviral (ARV) combination therapy, plans to put the technology in a free access patent pool, two company executives said, requesting anonymity…” (Unnirkishnan, 3/10).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.